Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 01, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of May 31, 2007, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Share Capital (as of May 31, 2007) | 6,020,593,449 Ordinary shares of 25p each |
| Treasury Shares | 303,069,158 Ordinary shares |
| Total Voting Rights | 5,717,524,291 |
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in financial performance or capital structure.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, contingencies, or unusual items. It is a statutory notification intended to assist shareholders in calculating disclosure thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,717,524,291) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (303,069,158) to understand the float.
- Note that this document does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.